<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413269</url>
  </required_header>
  <id_info>
    <org_study_id>CH-BC-013</org_study_id>
    <nct_id>NCT01413269</nct_id>
  </id_info>
  <brief_title>Randomized Study of Hypofractionated and Conventional Fractionation Radiotherapy After Breast Conservative Surgery</brief_title>
  <official_title>Phase 3 Open-labeled Randomized Clinical Study of Comparing Hypofractionated and Conventional Radiotherapy for Breast Cancer Patients After Breast Conservative Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early-stage breast cancer patients treated with breast conservative surgery are enrolled in
      this study if they meet defined criteria. Patients are randomized into two groups:
      conventional fractionation radiotherapy and hypofractionated radiotherapy.The hypothesis is
      that conventional fractionation radiotherapy and hypofractionated radiotherapy have similar
      efficacy and toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>in-breast recurrence rate</measure>
    <time_frame>5 year</time_frame>
    <description>evidence of ipsilateral breast local recurrence confirmed by histology</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>regional node recurrence rate</measure>
    <time_frame>5 year</time_frame>
    <description>ipsilateral axillary node, internal mammary node and supraclavicular node recurrence confirmed by physical examination, image evaluation or histology.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>5 year</time_frame>
    <description>locoregional relapse, distant relapse, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>5 year</time_frame>
    <description>any death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity</measure>
    <time_frame>6 months</time_frame>
    <description>radiation dermatitis and radiation pneumonitis evaluated and graded by CTC3.0 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late complication</measure>
    <time_frame>3 -10 year</time_frame>
    <description>breast cosmetic effect, ischemic heart disease, rib fracture, arm edema and shoulder joint dysfunction</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">720</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>hypofractionation radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irradiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional fractionation radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>irradiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiotherapy</intervention_name>
    <description>one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.
the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week.</description>
    <arm_group_label>hypofractionation radiotherapy</arm_group_label>
    <arm_group_label>conventional fractionation radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. KPS&gt;=60

          2. histology confirmed invasive breast cancer

          3. received breast conservative surgery(wide local excision and axilla dissection, or
             axillary sentinel node biopsy if sentinel node is negative)

          4. surgical margins negative

          5. primary tumor ≤5cm in the largest diameter

          6. no internal mammary node or supraclavicular node metastases or distant metastasis

          7. can tolerate chemotherapy,hormone therapy (if needed) and radiotherapy

          8. for patients not need chemotherapy，enrollment date is required no more than 8 weeks
             from surgery date

          9. for patients with chemotherapy first,enrollment date is required no more than 8 weeks
             from the last date of chemotherapy

         10. patients signed written inform consent form

        Exclusion Criteria:

          1. ductal carcinoma in situ

          2. prior neoadjuvant chemotherapy

          3. prior breast cancer history

          4. bilateral breast cancer

          5. pregnant or during lactation

          6. prior or concomitant malignant tumor excluded skin cancer(not malignant melanoma) and
             cervix carcinoma in situ

          7. active collagen vascular disease

          8. prior neoadjuvant hormone therapy

          9. immediate ipsilateral breast reconstruction
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ye-xiong Li, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shu-lian Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hang-zhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <last_update_submitted>July 20, 2017</last_update_submitted>
  <last_update_submitted_qc>July 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Shu lian Wang</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>breast cancer patients</keyword>
  <keyword>breast conservation surgery</keyword>
  <keyword>hypofractionated radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

